


Amendments to the Claims:

Claims 10-17 and 19-37 are canceled without prejudice, Claims 1-9 and 18 are amended, and Claims 38-42 are added by the present amendment. This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A 3-heteroarylidene-2-indolinone having the chemical structure:



or a physiologically acceptable salt ~~or prodrug~~ thereof wherein,

A, B, D and E are carbon

R¹ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, hydroxy, alkoxy, carboxyl, C-amido and sulfonyl;

R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heteroalicyclic;


R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonamido, carbonyl,

carboxyl, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and -NR¹⁰R¹¹;

R¹⁰ and R¹¹ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl and, combined, a five- or six-member heteroalicyclic ring containing at least one nitrogen;

R³ and R⁴, R⁴ and R⁵, or R⁴ and R⁵ may combine to form a six-member aryl or heteroaryl ring;

Q is a heteroaryl group having the following structure:



J is selected from the group consisting of oxygen, nitrogen and sulfur;

K, L and M are independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur such that the five-member heteroaryl ring formed is one known in the chemical arts, it being understood that when K, L and M are nitrogen, sulfur or oxygen, R⁸ or -(alk₁)_nZ cannot be covalently bonded to that atom;

when J is nitrogen, R⁷ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, hydroxy, alkoxy, aryloxy, carbonyl, carboxyl, C-amido, guanyl and sulfonyl and when J is oxygen or sulfur, R⁷ does not exist and there is no bond;

R⁸ is selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy,

thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonamido, carbonyl, carboxyl, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino, -NR¹⁰R¹¹, trihalomethyl, a five member cycloalkyl, aryl, heteroaryl or heteroalicyclic **heteoalicyclic** ring fused to two adjacent atoms of the Q ring; and a six-member cycloalkyl **cycloalky**, aryl, heteroaryl, or heteroalicyclic ring fused to two adjacent atoms of the Q ring;

R¹⁰ and R¹¹ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl and, combined, a five- or six-member heteroalicyclic ring containing at least one nitrogen;

alk₁ is selected from the group consisting of optionally substituted methylene (-CRR'-), optionally substituted ethylene (-C(R)=C(R')-) and acetylene (-C≡C-);

R and R' are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, alkoxy, thioalkoxy, aryloxy and halo;

n is 0 to 10, inclusive;

and Z is a polar group.

2. (Currently Amended) The compound or salt, salt or prodrug of claim 1 wherein, K, L and M are carbon;

R⁸ is selected from the group consisting of hydrogen, alkyl, halo, cyano, carboxyl, a six-member cycloalkyl group fused to 2 adjacent atoms of the Q ring and a six-member heteroalicyclic ring fused to 2 adjacent atoms of the Q ring;

alk₁ is selected from the group consisting of CH₂ and CH₂CH₂;

n is 0, 1, 2 or 3;

and, Z is selected from the group consisting of hydroxy, alkoxy, amino, carboxyl, carbamyl, amido, morpholino, piperazinyl, tetrazolo, sulfonyl, sulfonamido, ureido and phosphonyl.

3. (Currently Amended) The compound or salt, salt or prodrug of claim 2 wherein, J is nitrogen.

4. (Currently Amended) The compound or salt, salt or prodrug of claim 2 wherein, J is sulfur.

5. (Currently Amended) The compound or salt, salt or prodrug of claim 2 wherein, J is oxygen.

6. (Currently Amended) The compound or salt, salt or prodrug of claim 3 wherein, R⁷ is hydrogen.

7. (Currently Amended) The compound or salt, salt or prodrug of claim 2 wherein,

R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, alkoxy, halo, amino and -NR¹⁰R¹¹; and,

R¹⁰ and R¹¹ are independently selected from the group consisting of hydrogen, alkyl, carbonyl and sulfonyl.

8. (Currently Amended) The compound or salt, salt or prodrug of claim 7 wherein, R¹ is hydrogen.

9. (Currently Amended) The compound or salt, salt or prodrug of claim 1 wherein,

J and L are nitrogen;

R⁷ is selected from the group consisting of:

unsubstituted lower alkyl;

unsubstituted aryl;

unsubstituted heteroaryl;

unsubstituted heteroalicyclic;
sulfonyl;
unsubstituted lower alkoxy;
trihalomethanesulfonyl;
aryl substituted with one of more groups independently selected from the group
consisting of:

halo;
amino;
hydroxy;
cyano;
unsubstituted lower alkyl;
unsubstituted lower alkoxy;
carboxyl;
S-sulfonamido;
lower alkyl substituted with one or more groups selected from the group
consisting of:

halo;
hydroxy;
amino; and
carboxyl; and -earboxyl; or,
lower alkoxy substituted with one or more halo groups;
heteroaryl substituted with one or more groups independently selected from the
group consisting of:

halo;
amino;
hydroxy;
cyano;
unsubstituted lower alkyl;
unsubstituted lower alkoxy;
carboxyl;
S-sulfonamido;
lower alkyl substituted with one or more groups selected from the group
consisting of:

halo;
hydroxy;
amino; and
carboxyl; and carboxyl; or,

lower alkoxy substituted with one or more halo groups;

R^8 is selected from the group consisting of:

unsubstituted lower alkyl;
lower alkyl substituted with one or more groups selected from the group
consisting of:

halo;
hydroxyl;
unsubstituted lower alkoxy;
amino; and amino; or,

carboxyl;
unsubstituted lower alkoxy;
lower alkoxy substituted with one or more halo groups;
unsubstituted aryl;
unsubstituted heteroaryl
unsubstituted heteroalicyclic
aryl substituted with one or more groups independently selected from the group
consisting of:
halogen;
hydroxy;
carboxyl;
nitro;
cyano;
amino;
 $-\text{NR}^{10}\text{R}^{11}$;
S-sulfonamido;
unsubstituted lower alkoxy;
lower alkoxy substituted with one or more halogens;
unsubstituted lower alkyl;
lower alkyl substituted with one or more groups selected from the group
consisting of:

halogen;

hydroxy;

amino;

-NR¹⁰R¹¹; and -NR¹⁰R¹¹; or,

carboxyl

heteroaryl substituted with one or more groups independently selected from the group consisting of:

halogen;

hydroxy;

carboxyl;

nitro;

cyano;

amino;

S-sulfonamido;

unsubstituted lower alkoxy;

lower alkoxy substituted with one or more halogens;

unsubstituted lower alkyl; and

lower alkyl substituted with one or more groups selected from the group consisting of:

halogen;

hydroxy;

amino;

-NR¹⁰R¹¹; and -NR¹⁰R¹¹; or,

carboxyl;

heteroalicyclic substituted with one or more groups independently selected from the group consisting of:

halogen;

hydroxy;

carboxyl;

nitro;

cyano;

amino;

$-\text{NR}^{10}\text{R}^{11}$;

S-sulfonamido;

unsubstituted lower alkoxy;

lower alkoxy substituted with one or more halogens;

unsubstituted lower alkyl;

lower alkyl substituted with one or more groups selected from the group consisting of:

halogen;

hydroxy;

amino;

$-\text{NR}^{10}\text{R}^{11}$; and $-\text{NR}^{10}\text{R}^{11}$; or,

carboxyl; and,

R^3 , R^4 , R^5 and R^6 are independently selected from the groups consisting of hydrogen, halogen, nitro, amino, cyano, S-sulfonamido, carboxyl, trihalomethyl, unsubstituted lower alkyl and lower alkyl substituted with one or more groups selected from the group consisting of

halogen, hydroxyl, carboxyl, unsubstituted lower alkoxy and lower alkoxy substituted with one or more halo groups.

10-17. (Canceled)

18. (Currently amended) A pharmacological composition of said compound or ~~salt, salt or prodrug~~ of claim 1.

19-37. (Canceled)

38. (New) A method for the modulation of the catalytic activity of a protein kinase comprising contacting said protein kinase with said compound or salt of claim 1 wherein said protein kinase is selected from the group consisting of EGF, HER2, IGF-1R, PDGFR α , PDGFR β , Flk-1R, Met, Src, Lck, CDK2 and Raf.

39. (New) A method for treating a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of said pharmacological composition of claim 18 to said organism wherein said protein kinase related disorder is an angiogenesis related disorder.

40. (New) The method of claim 39 wherein the angiogenesis related disorder is breast cancer.

41. (New) The method of claim 39 wherein said organism is a mammal.

42. (New) The method of claim 41 wherein said mammal is a human.